UroToday.com(@urotoday) 's Twitter Profile Photo

Can simplified PADUA Renal (SPARE) nephrometry scoring system help predict renal function outcomes after robot-assisted partial nephrectomy? ( Study 93). > bit.ly/3VRtJ1V Clément Klein Gaëlle Margue Cécile CHAMPY Bastien Parier Waeckel Thibaut

Can simplified PADUA Renal (SPARE) nephrometry scoring system help predict renal function outcomes after robot-assisted partial nephrectomy? (#UroCCR Study 93). #BeyondTheAbstract > bit.ly/3VRtJ1V @Clem_klein @GaelleMargue @CecileChampy @ParierBastien @WaeckelT
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

Prognostic value of pretreatment inflammatory markers in localized before radical prostatectomy. with Josias Bastian Grogg and Cédric Poyet Unispital_USZ. on UroToday > bit.ly/3Pypc0j @WJUrol

Prognostic value of pretreatment inflammatory markers in localized #ProstateCancer before radical prostatectomy. #BeyondTheAbstract with Josias Bastian Grogg and @CPMS1B @Unispital_USZ. #ReadNow on UroToday > bit.ly/3Pypc0j @wjurol
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

New insights into managing clinically lymph-node positive ! Hanjie Lee & Kenneth Chen discuss a systematic review & meta-analysis examining the role of local therapy alongside traditional androgen deprivation therapy > bit.ly/49Nf9Mx

New insights into managing clinically lymph-node positive #prostatecancer! Hanjie Lee & Kenneth Chen discuss a systematic review & meta-analysis examining the role of local therapy alongside traditional androgen deprivation therapy > bit.ly/49Nf9Mx #BeyondTheAbstract
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

MRI-based radiomics analysis of levator ani muscle for predicting urine incontinence after robot-assisted radical prostatectomy. on UroToday > bit.ly/4afE1gc Mohammed Shahait Alex Sandberg

MRI-based radiomics analysis of levator ani muscle for predicting urine incontinence after robot-assisted radical prostatectomy. #BeyondTheAbstract on UroToday >  bit.ly/4afE1gc @MShahait @alex_sandberg11
account_circle
Smart City Innovation Cluster(@scic_fin) 's Twitter Profile Photo

Tampere Smart City Expo & Conference @_tscec was fruitful in means of encounters and new connections. Great conversations during the day at the booth with ITS Finland and Business Tampere. New innovative members were acquired as well.

Tampere Smart City Expo & Conference @_tscec was fruitful in means of encounters and new connections. Great conversations during the day at the booth with @ITS_Finland and @BusinessTampere. New innovative members were acquired as well.

#smartcities #tscec #beyondtheabstract
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

Ethnic differences in presentation: A time for testing advocacy. with Deepak Batura London North West University Healthcare discusses work that underscores the point that these variations need to be studied further to develop targeted interventions > bit.ly/3uJtVVB

Ethnic differences in #ProstateCancer presentation: A time for testing advocacy. #BeyondTheAbstract with @DeepakBatura @LNWH_NHS discusses work that underscores the point that these variations need to be studied further to develop targeted interventions > bit.ly/3uJtVVB
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

Patient-reported outcomes with olaparib + abiraterone vs PBO + abi for : a randomized, double-blind, phase 2 trial. with Fred Saad, MD, FRCS CHUM and Noel Clarke, MBBS, ChM, FRCS The Christie NHS. on UroToday > bit.ly/3wtFGjy

Patient-reported outcomes with olaparib + abiraterone vs PBO + abi for #mCRPC: a randomized, double-blind, phase 2 trial. #BeyondTheAbstract with Fred Saad, MD, FRCS @chumontreal and Noel Clarke, MBBS, ChM, FRCS @TheChristieNHS. #ReadNow on UroToday > bit.ly/3wtFGjy
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

A phase I clinical trial evaluating the safety and dosing of relugolix with novel hormonal therapy for the treatment of advanced . with Jose De La Cerda, MD Urology San Antonio on UroToday > bit.ly/3TlYxVm Targeted Oncology

A phase I clinical trial evaluating the safety and dosing of relugolix with novel hormonal therapy for the treatment of advanced #ProstateCancer. #BeyondTheAbstract with Jose De La Cerda, MD @UrologySA on UroToday > bit.ly/3TlYxVm @TargetedOnc
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

Atezolizumab monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma : Final overall survival analysis from a randomized, controlled, phase 3 study. on UroToday > bit.ly/3WwQ7xV The Lancet Oncology

Atezolizumab monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma #IMvigor130: Final overall survival analysis from a randomized, controlled, phase 3 study. #BeyondTheAbstract on UroToday > bit.ly/3WwQ7xV @TheLancetOncol
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

Laser ablation efficiency, laser ablation speed, and laser energy consumption during lithotripsy: What are they and how are they defined? A systematic review and proposal for a standardized terminology. with Jia-Lun Kwok and Etienne Xavier Keller > bit.ly/48nYJcc

Laser ablation efficiency, laser ablation speed, and laser energy consumption during lithotripsy: What are they and how are they defined? A systematic review and proposal for a standardized terminology. #BeyondTheAbstract with @jl_kwok and @exkeller > bit.ly/48nYJcc
account_circle